Literature DB >> 16082570

Plasmatic [corrected] factor XIII reduces severe pleural effusion in children after open-heart surgery.

M Schroth1, U Meißner2, R Cesnjevar3, M Weyand3, H Singer2, W Rascher2, J Klinge2.   

Abstract

Chylous effusions frequently occur after cardiac surgery due to severe damage to the lymphatic system, thus indicating that the insertion of a chest tube may be necessary. Factor XIII (FXIII) is discussed as being essential for wound healing. The aim of this retrospective study was to evaluate whether the application of a single dose of FXIII results in a reduced amount of pleural effusion, leading to an earlier release of patients from the hospital. The cases of 40 children with severe chylous effusions after open-heart surgery were examined. Twenty patients received FXIII and were compared to 20 age- and weight-matched patients who did not receive FXIII. Major parameters included the amount of effusion before and 1 and 3 days after the application of FXIII; the duration of chest tubes; the total amount of fluid loss via drainage; and the period of hospitalization. FXIII levels in plasma showed an inverse correlation with fluid loss. After application of a single dose of FXIII, a significant reduction of pleural effusion within the first 24 hours was detected. However, no difference was observed between the two groups when comparing the total amount of pleural effusions within the first 72 hours. Finally, the duration of hospitalization did not differ between the FXIII-treated and the control group. A single application of FXIII rapidly reduces the amount of chylous effusions in the early period after open-heart surgery. This effect is detectable only for 24 hours after the treatment and does not alter the further clinical outcome. Prospective clinical trials are warranted to determine if repeated application or a higher dose of FXIII may improve the clinical outcome of chylous leakages in children after open-heart surgery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16082570     DOI: 10.1007/s00246-005-0993-5

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  29 in total

1.  Fibrin sealants in supporting surgical techniques: The importance of individual components.

Authors:  Gernold Wozniak
Journal:  Cardiovasc Surg       Date:  2003-08

Review 2.  Fibrin sealant: a review of its use in surgery and endoscopy.

Authors:  C J Dunn; K L Goa
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

3.  Fibrin clots.

Authors:  L LORAND
Journal:  Nature       Date:  1950-10-21       Impact factor: 49.962

4.  [Chylothorax after blunt thoracic trauma].

Authors:  A Platz; H P Simmen; M Heinzelmann; A Kohler; O Trentz
Journal:  Chirurg       Date:  1995-02       Impact factor: 0.955

5.  Factor XIII substitution in ulcerative colitis.

Authors:  R Lorenz; P Born; P Olbert; M Classen
Journal:  Lancet       Date:  1995-02-18       Impact factor: 79.321

6.  Factor XIII modulates intestinal epithelial wound healing in vitro.

Authors:  E Cario; H Goebell; A U Dignass
Journal:  Scand J Gastroenterol       Date:  1999-05       Impact factor: 2.423

Review 7.  Physiopathology and regulation of factor XIII.

Authors:  A Ichinose
Journal:  Thromb Haemost       Date:  2001-07       Impact factor: 5.249

8.  Transthoracic intracardiac catheters in pediatric patients recovering from congenital heart defect surgery: associated complications and outcomes.

Authors:  H R Flori; L D Johnson; F L Hanley; J R Fineman
Journal:  Crit Care Med       Date:  2000-08       Impact factor: 7.598

Review 9.  The use of human fibrin glue in the surgical operations.

Authors:  Silvestro Canonico
Journal:  Acta Biomed       Date:  2003

10.  Novel proangiogenic effect of factor XIII associated with suppression of thrombospondin 1 expression.

Authors:  Rima Dardik; Arieh Solomon; Joseph Loscalzo; Regina Eskaraev; Ann Bialik; Iris Goldberg; Ginette Schiby; Aida Inbal
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-06-12       Impact factor: 8.311

View more
  6 in total

Review 1.  Roles of transglutaminases in cardiac and vascular diseases.

Authors:  David C Sane; Jimmy L Kontos; Charles S Greenberg
Journal:  Front Biosci       Date:  2007-01-01

2.  Management of Aortic Replacement-Induced Chylothorax by Lipiodol Lymphography.

Authors:  Hiroto Kitahara; Akihiro Yoshitake; Takashi Hachiya; Yu Inaba; Kentaro Tamura; Hideki Yashiro; Seiji Nakatsuka; Hideyuki Shimizu
Journal:  Ann Vasc Dis       Date:  2015-05-25

3.  Coagulation Factor XIII Subunit A Is a Biomarker for Curative Effects and Prognosis in Malignant Solid Tumors, Especially Non-small Cell Lung Cancer.

Authors:  Yujiao Luo; Bin Li; Ji Li; Yang Zhang; Mingyang Deng; Chunhong Hu; Wenzhe Yan; Zhiguang Zhou; Guangsen Zhang
Journal:  Front Oncol       Date:  2021-12-15       Impact factor: 6.244

4.  Influence of factor XIII activity on post-operative transfusion in congenital cardiac surgery-A retrospective analysis.

Authors:  Fabian B Fahlbusch; Thomas Heinlein; Manfred Rauh; Sven Dittrich; Robert Cesnjevar; Julia Moosmann; Jennifer Nadal; Matthias Schmid; Frank Muench; Michael Schroth; Wolfgang Rascher; Hans-Georg Topf
Journal:  PLoS One       Date:  2018-07-10       Impact factor: 3.240

5.  Neutrophil-to-lymphocyte ratio is prognostic factor of prolonged pleural effusion after pediatric cardiac surgery.

Authors:  Kazuki Yakuwa; Kagami Miyaji; Tadashi Kitamura; Takashi Miyamoto; Minoru Ono; Yukihiro Kaneko
Journal:  JRSM Cardiovasc Dis       Date:  2021-04-19

Review 6.  Factor XIII-A: An Indispensable "Factor" in Haemostasis and Wound Healing.

Authors:  Fahad S M Alshehri; Claire S Whyte; Nicola J Mutch
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.